Anturol

Patient Information

ANTUROL
[an’-ter-all]
(oxybutynin) gel 3% Topical

Important: For use on the skin only (topical). Do not get ANTUROL in or near your eyes, nose, or mouth.

Read this Patient Information carefully before you start taking ANTUROL and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.

What is ANTUROL?

ANTUROL is a prescription medicine used to treat the symptoms of overactive bladder including:

• a strong need to urinate with leaking or wetting accidents (urge urinary incontinence)
• a strong need to urinate right away (urgency)
• urinating often (frequency)

It is not known if ANTUROL is safe or effective in children.

Who should not use ANTUROL?

Do not use ANTUROL if:

• Your bladder does not empty or does not empty completely when you urinate (urinary retention).
• Your stomach empties slowly or incompletely after a meal (gastric retention).
• You have high pressure in your eye (uncontrolled narrow-angle glaucoma).
• You have an allergy to oxybutynin or any of the ingredients in ANTUROL. See the end of this leaflet for a complete list of ingredients in ANTUROL.

Talk to your healthcare provider before taking this medicine if you have any of these conditions.

What should I tell my doctor before using ANTUROL?

Before you take ANTUROL, tell your doctor if you:

• have problems emptying your bladder completely
• have stomach problems including:
  • constipation or difficulty in emptying your bowels
  • inflamed bowels (ulcerative colitis)
  • inflammation of the tube between your mouth and stomach (gastric reflux disease or esophagitis)
• have generalized muscle weakness (Myasthenia Gravis)
• are pregnant or are planning to become pregnant. It is not known if ANTUROL will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if ANTUROL passes into your breast milk. Talk to your doctor about the best way to feed your baby if you use ANTUROL.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

ANTUROL may affect the way other medicines work, and other medicines may affect how ANTUROL works. Especially tell your doctor if you take:

• medicines used to treat osteoporosis (Bisphosphonates)
• other medicines used to treat overactive bladder (Anticholinergic)

Ask your doctor if you are not sure if your medicine is one listed above.

Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.

How should I use ANTUROL?

ANTUROL is for skin use only.

• Use ANTUROL exactly as your doctor tells you to use it.
• ANTUROL should only be applied to dry intact skin on your stomach (abdomen), upper arms, or thighs.
• Do not put ANTUROL on recently shaved skin, open sores, scars, tattoos, or skin with rashes.
• Do not put ANTUROL on your breasts or genital area.
• ANTUROL contains alcohol and is flammable. Avoid fire, flames, or smoking until the ANTUROL has dried.
• Cover the application site with clothing after the gel has dried, if skin-to-skin contact between another person and the application site is expected.
• After applying ANTUROL, wash your hands with soap and water right away.
• ANTUROL may be used with sunscreen.
• If you get ANTUROL in your eyes: Rinse your eyes well right away with clean and warm water. Seek medical attention if needed.

How to use the ANTUROL pump:

You must prime the ANTUROL pump before you use it for the first time.

To prime the pump:

• To prime the Anturol pump, hold the pump upright and fully press down (depress) the pump 4 times. Now Anturol is ready to use.
• Do not use any Anturol that came out while priming.

Applying ANTUROL:

1. Selecting your application site:

Apply ANTUROL only to 1 of the shaded areas shown in the figure below: (See (Figure A)).

• stomach area (abdomen)
• upper arms
• shoulders
• thighs

(Figure A)

• Wash the area where ANTUROL will be applied with mild soap and water. Allow the area to dry completely.
• Wash your hands with soap and water.
• Application sites may be rotated to reduce the potential for local site reactions.

2. Dispensing your dose of ANTUROL:

• Place your hand under the ANTUROL pump.
• Press the pump all the way down 3 times (See (Figure B). You can also place the pump right over the application site then press the pump all the way down 3 times to dispense your dose (See (Figure C).
• You should apply ANTUROL right after you dispense your dose.
• Wash your hands with soap and water right away.

(Figure B)

What should I avoid while using ANTUROL?

• Do not take a bath, swim, shower, exercise, or get the application site wet for 1 hour after you apply your dose.
• ANTUROL can cause dizziness or blurred vision. Do not drive, operate heavy machinery, or do other dangerous activities until you know how ANTUROL affects you.
• You should not drink alcohol while using ANTUROL. It can increase your chances of getting serious side effects.

(Figure C)

What are the possible side effects of ANTUROL?

The most common side effects of ANTUROL include:

• dry mouth
• urinary tract infections
• dry eyes
• blurry vision
• redness, rash, itching, pain at the application site

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of ANTUROL. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

How should I store ANTUROL?

• Store ANTUROL at room temperature between 68°F to 77°F (20°C to 25°C).

Keep ANTUROL and all medicines out of the reach of children.

General information about the safe and effective use of ANTUROL.

Medicines are sometimes prescribed for conditions that are not mentioned in the patient information leaflet. Do not use ANTUROL for a condition for which it was not prescribed. Do not give ANTUROL to other people, even if they have the same symptoms you have. It may harm them.

This Patient Information leaflet summarizes the most important information about ANTUROL. If you would like more information about ANTUROL, talk with your doctor. You can ask your pharmacist or doctor for information about ANTUROL that is written for health professionals.

For more information go to www.ANTUROLGEL.com or call 1-800-328-3077.

What are the ingredients in ANTUROL?

Active ingredient: oxybutynin

Inactive ingredients: diethylene glycol monoethyl ether, NF; alcohol, USP; hydroxypropyl cellulose, NF; propylene glycol, NF; butylated hydroxytoluene, NF; HC1 0.1 M, NF; and purified water, USP.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Description

Oxybutynin is an antispasmodic, antimuscarinic agent. ANTUROL (oxybutynin) gel 3% is a topical, homogeneous, very lightly to moderately opalescent, translucent colorless to slightly colored gel, without particles hydroalcoholic gel containing 30 mg oxybutynin per gram of gel. ANTUROL is available in a 0.92 gram (1 mL) unit dose that contains 28 mg oxybutynin. Oxybutynin is delivered as a racemate of R- and S-isomers. Chemically, oxybutynin base is d, 1 (racemic) 4-(Diethylamino)-2-butynyl (±)-α- phenylcyclohexaneglycolate.

The empirical formula of oxybutynin base is C₂₂H₃₁NO₃. Its structural formula is:

Oxybutynin is a white powder with a molecular weight of 357. Inactive ingredients in ANTUROL are diethylene glycol monoethyl ether, NF; alcohol, USP; hydroxypropyl cellulose, NF; propylene glycol, NF; butylated hydroxytoluene, NF; HC1 0.1 M, NF; and purified water, USP.

Indications

ANTUROL (oxybutynin) gel 3% is a muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see Clinical Studies].

Dosage And Administration

The recommended dosage is three pumps of ANTUROL (84 mg/day) applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs. Apply immediately after actuating the dose. Application sites may be rotated to reduce the potential for local site reactions [see ADVERSE REACTIONS]. ANTUROL is for topical application only and should not be ingested. Wash hands immediately after product application. Patients should cover the application site with clothing after the gel has dried if direct skin-to-skin contact at the application site is anticipated [see WARNINGS AND PRECAUTIONS].

How Supplied

Dosage Forms and Strengths

ANTUROL is a homogeneous, colorless to slightly colored gel 3%.

ANTUROL (oxybutynin) gel 3% is supplied in a metered-dose pump dispenser composed of an inner aluminum laminated foil liner encased in a rigid plastic bottle with a plastic cap. The nozzle of the pump dispenser is sealed by a removable cap attached to the actuator by a plastic string.

How Supplied

55948-301-01 2 x 45 mL (2 x 42g) metered pump dispensers each containing 30 metered 0.92 g (1.0 mL) pumps delivering 28 mg oxybutynin per pump actuation.

55948-301-02 100 mL (92g) metered pump dispenser containing 90 metered 0.92 g (1 mL) pumps delivering 28 mg oxybutynin per pump actuation.

Storage

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). See USP controlled room temperature. Protect from moisture and humidity.

Antares Pharma, Inc. Ewing, NJ 08618 USA. Issued: December 2011

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.

The safety of ANTUROL was evaluated in 626 patients (210 randomized to ANTUROL 56 mg/day, 214 randomized to ANTUROL 84 mg/day and 202 randomized to placebo) during a randomized, placebo-controlled, double-blind, 12-week clinical efficacy and safety study. A subset of these 626 patients (N = 77) participated in the 24-week open-label safety extension that followed the placebo-controlled study. Of the 77 patients in the safety extension, 24 were randomized to placebo gel during the double-blind, placebo-controlled 12-week study. In the combined double-blind, placebo-controlled study and the open-label safety extension, a total of 441 patients were exposed to at least one dose of ANTUROL. 364 patients received at least 12 weeks of ANTUROL treatment and 66 patients received an additional 24 weeks of ANTUROL treatment during the open-label safety extension. The study population primarily consisted of women (87%) of Caucasian descent (87%) with an average age of 59 years who had overactive bladder with urge urinary incontinence.

Table 1 lists adverse reactions (ARs), regardless of causality, that were reported in the randomized, double-blind, placebo-controlled 12-week study at an incidence greater than placebo and in greater than 3% of patients treated with ANTUROL.

Overall, 672 ARs were experienced by 51.9% of patients. Majority of the ARs were mild to moderate in intensity. The AR most commonly reported was dry mouth which was experienced by a greater proportion of patients in the oxybutynin group than the placebo group (26 patients [12.1%] in the oxybutynin 84 mg group, 10 patients [5.0%] in the placebo group). Application site erythema was the next most commonly reported AR (8 patients [3.7%] in the oxybutynin 84 mg group and 2 patients [1.0%] in the placebo group). Other commonly reported ARs experienced by more patients in the oxybutynin groups compared with placebo were application site rash (7 patients [3.3%] in the oxybutynin 84 mg group and 1 patient [0.5%] in the placebo group); application site pruritus (6 patients [2.8%] in the oxybutynin 84 mg group and 1 patient [0.5%] in the placebo group). The overall rate of application site adverse reactions of any kind was 14.2% in patients receiving ANTUROL as compared to 3.7% in patients receiving placebo. Other cholinergic AEs < 2% in occurrence include dry eyes and blurred vision.

There were no deaths during the study. There were no clinically meaningful changes in vital signs, laboratory values, or ECG examinations over the course of the study.

Table 1: Commonly Reported Adverse Reactions that were reported In greater than 3% of patients treated with ANTUROL and at an incidence greater than placebo.

Preferred Term1	Treatment Group
	Oxybutynin 84 mg/day (N=214)	Placebo (N=202)
	n (%)	n (%)
Dry mouth	26 (12.1)	10 (5.0)
Application site erythema	8 (3.7)	2 (1.0)
Application site rash	7 (3.3)	1 (0.5)
1 Each patient is counted only once within each treatment, body system and preferred term. All percentages are based on number of patients in the ITT population within each treatment group as denominator.

During the 24-week open-label safety extension, the most commonly reported ARs were urinary tract infection and nasopharyngitis reported in 4 patients each (5.2%), followed by conjunctivitis and application site erythema (both occurred in 3 patients [3.9%]). One patient prematurely discontinued due to the application site erythema and pruritus (both considered to be of mild severity).

Drug Interactions

No specific drug-drug interaction studies have been performed with ANTUROL.

Other Anticholinergics

The concomitant use of ANTUROL with other anticholinergic (antimuscarinic) agents may increase the frequency and/or severity of dry mouth, blurred vision, and other anticholinergic pharmacological effects.

Included as part of the PRECAUTIONS section.

Precautions

Urinary Retention

Use ANTUROL with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.

Use In Patients with Gastrointestinal Disorders

Use ANTUROL with caution in patients with gastrointestinal obstructive disorders because of the risk of gastric retention. ANTUROL, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis or intestinal atony. ANTUROL should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis.

Skin Transference

Transfer of oxybutynin to another person can occur when vigorous bare skin-to-skin contact is made with the application site. To minimize the potential transfer of oxybutynin from ANTUROL -treated skin to another person, patients should cover the application site with clothing after the gel has dried if direct skin-to-skin contact at the application site is anticipated [see CLINICAL PHARMACOLOGY]. Patients should wash their hands immediately after application of ANTUROL.

Flammable Gel

ANTUROL is an alcohol-based gel and is therefore flammable. Avoid open fire or smoking until gel has dried.

Myasthenia Gravis

Administer ANTUROL with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.

Angioedema

Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oral oxybutynin. In the event of angioedema, oxybutynin containing product should be discontinued and appropriate therapy promptly provided.

Controlled Narrow-Angle Glaucoma

Administer ANTUROL with caution in patients being treated for narrow-angle glaucoma.

Patient Counseling Information

“See FDA-approved patient labeling (PATIENT INFORMATION)”

Instructions for Use

Inform patients of the following:

• ANTUROL is for topical application only and should not be ingested. Keep out of reach of children.
• ANTUROL should be applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs.
• Do not use any ANTUROL that came out while priming.
• Apply immediately after actuating the dose.
• Application sites may be rotated to reduce the potential for local site reactions
• ANTUROL should not be applied to recently shaved skin surfaces. Avoid skin with open sores, wounds, irritation, scars, and tattoos.
• Do not apply the gel to the breasts or genital area.
• Discard used pump dispensers in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.
• Wash hands immediately after product application.
• Do not shower or immerse the application site in water for 1 hour after product application.
• Cover the application sites with clothing if skin-to-skin contact at the application site is anticipated.
• Alcohol based gels are flammable. Avoid open fire or smoking until the gel has dried.
• If you get ANTUROL in your eyes, thoroughly rinse your eyes right away with warm, clean water to flush out any ANTUROL. Seek medical attention if needed.

Important Anticholinergic Adverse Reactions

Patients should be informed that anticholinergic (antimuscarinic) agents, such as ANTUROL, may produce clinically significant adverse reactions related to anticholinergic pharmacological activity. Heat prostration (due to decreased sweating) can occur when anticholinergics such as ANTUROL are used in a hot environment. Because anticholinergic (antimuscarinic) agents, such as ANTUROL, may produce dizziness or blurred vision, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until ANTUROL’s effects have been determined. Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic (antimuscarinic) agents such as ANTUROL.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

A 24-month study in rats at dosages of oxybutynin chloride of 20, 80 and 160 mg/kg showed no evidence of carcinogenicity. These doses are approximately 6, 25 and 50 times the maximum exposure in humans taking an oral dose, based on body surface area. Oxybutynin chloride showed no increase of mutagenic activity when tested in Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae, and Salmonella typhimurium test systems. Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no evidence of impaired fertility.

Use In Specific Populations

Pregnancy

Pregnancy Category B

There are no adequate and well-controlled studies of topical or oral oxybutynin use in pregnant women. Reproduction studies using oxybutynin chloride in the hamster, rabbit, rat, and mouse have shown no evidence of impaired fertility or harm to the fetus. The safety of ANTUROL administration to women who are or who may become pregnant has not been established. Therefore, ANTUROL should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards.

Labor and Delivery

ANTUROL has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.

Nursing Mothers

It is not known whether oxybutynin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ANTUROL is administered to a nursing woman.

Pediatric Use

This drug product should not be used in children because the safety and effectiveness of ANTUROL has not been established in pediatric patients.

Geriatric Use

Of the 424 patients exposed to ANTUROL in the randomized, double-blind, placebo-controlled 12-week study, 182 patients (34%) were 65 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients.

Renal Impairment

Patients with renal impairment received ANTUROL during clinical trials. These trials were not designed to determine whether there were differences in safety or effectiveness in patients with or without impaired renal function.

Hepatic Impairment

Patients with hepatic impairment received ANTUROL during clinical trials. These trials were not designed to determine whether there were differences in safety or effectiveness in patients with or without impaired hepatic function.

Overdosage with oxybutynin has been associated with anticholinergic effects including central nervous system excitation, flushing, fever, dehydration, cardiac arrhythmia, vomiting, exhaustion, heat sensitivity, and urinary retention. Oral ingestion of 100 mg oxybutynin chloride in association with alcohol has been reported in a 13-year-old who experienced memory loss, and in a 34-year-old who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine. Both patients recovered fully with symptomatic treatment. If overexposure occurs, monitor patients until symptoms resolve.

Contraindications

The use of ANTUROL is contraindicated in patients with the following conditions:

• Urinary retention [see WARNINGS AND PRECAUTIONS].
• Gastric retention [see WARNINGS AND PRECAUTIONS].
• Uncontrolled narrow-angle glaucoma [see WARNINGS AND PRECAUTIONS].

Mechanism of Action

Oxybutynin is a racemic (50:50) mixture of R- and S- isomers. Antimuscarinic activity resides predominantly with the R-isomer. Oxybutynin acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. The active metabolite, N-desethyloxybutynin, has pharmacological activity on the human detrusor muscle that is similar to that of oxybutynin in in vitro studies. In patients with conditions characterized by involuntary detrusor contractions, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction.

Pharmacokinetics

Oxybutynin is transported across intact skin and into the systemic circulation by passive diffusion across the stratum corneum. Steady-state concentrations are achieved within 3 days of continuous dosing.

Absorption

Absorption of oxybutynin is similar when ANTUROL is applied to the abdomen, upper arm/shoulders or thighs. The pharmacokinetic parameters and mean plasma concentrations during a randomized, crossover study of the three recommended application sites in 25 healthy men and women are shown in Table 2 and Figure 1, respectively.

Table 2: Pharmacokinetic Parameters (mean values) for Oxybutynin (84 mg/day) 3% gel.

Application Site	AUC0-t (ng.h/mL)	Cmax (ng/mL)	Tmax (h)
Abdomen	284.1	6.3	24
Thigh	286.9	5.8	36
Upper Arm/Shoulder	329.1	8.8	24

Figure 1: Mean (including SD) plasma oxybutynin concentrations versus time after application of ANTUROL to the abdomen (Site A), thigh (Site B), and upper arm/shoulder (Site C) (N=25).

Distribution

Oxybutynin is widely distributed in body tissues following systemic absorption. The volume of distribution was estimated to be 193 L after intravenous administration of 5 mg oxybutynin chloride.

Metabolism

Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Metabolites include N-desethyloxybutynin (DEO), which is pharmacologically active and phenylcyclohexylglycolic acid, which is pharmacologically inactive.

Transdermal administration of oxybutynin bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyloxybutynin metabolite. Only small amounts of CYP3A4 are found in skin, limiting pre-systemic metabolism during transdermal absorption. The AUC ratio of N-desethyloxybutynin metabolite to parent compound following multiple transdermal applications is approximately 1:1 for ANTUROL. The apparent half-life was approximately 30 hours.

Excretion

Oxybutynin undergoes extensive hepatic metabolism, with less than 0.1% of the administered dose excreted unchanged in the urine. Less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.

Person-to-Person Transference

The potential for dermal transfer of oxybutynin from a treated person to an untreated person was evaluated in a single-dose study where subjects dosed with ANTUROL engaged in vigorous contact with an untreated partner for 15 minutes, either with (N=14 couples) or without (N=14 couples) clothing covering the application area. The untreated partners not protected by clothing demonstrated low detectable plasma concentrations of oxybutynin (mean Cmax = 0.65 ng/mL). Only one of the 14 untreated subjects participating in the clothing-to-skin contact regimen had very low measurable oxybutynin plasma concentrations (Cmax = 0.06 ng/mL) during the 24 hours following contact with treated subjects; oxybutynin was not detectable with the remaining 13 untreated subjects. Regardless of the low exposure observed in this study, patients should avoid skin-to-skin contact with partners after applying the gel.

Use of Sunscreen

The effect of sunscreen on the absorption of oxybutynin when applied 30 minutes before or 30 minutes after ANTUROL application was evaluated in a single-dose randomized crossover study (N=20). Concomitant application of sunscreen, either before or after ANTUROL application, had no effect on the systemic exposure of oxybutynin.

Showering

The effect of showering on the absorption of oxybutynin was evaluated in a randomized, steady-state crossover study under conditions of no shower, or showering 1, 2 or 6 hours after ANTUROL application (N=22). The results of the study indicate that showering one hour after administration does not affect the overall systemic exposure to oxybutynin.

Race

The effect of race on the pharmacokinetics of ANTUROL has not been studied.

Geriatric Patients

Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on geriatric status in patients following administration of ANTUROL [see Use In Specific Populations].

Pediatric Patients

The pharmacokinetics of oxybutynin and N-desethyloxybutynin following application of ANTUROL has not been evaluated in individuals younger than 18 years of age [see Use In Specific Populations].

Gender

Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on gender in healthy volunteers following administration of ANTUROL.

Renal Impairment

There is limited experience with the use of ANTUROL in patients with renal insufficiency [see Use In Specific Populations].

Hepatic Impairment

There is limited experience with the use of ANTUROL in patients with hepatic insufficiency [see Use In Specific Populations].

Clinical Studies

The efficacy and safety of ANTUROL was evaluated in a single randomized, double-blind, placebo-controlled, multicenter 12-week study in patients with urinary frequency and urge and mixed urinary incontinence with a predominance of urge incontinence episodes. This was followed by an open-label safety extension. Key entry criteria included adults with overactive bladder (OAB) symptoms for at least 3 months who were either treatment-naive or had demonstrated a beneficial response to anticholinergic treatment for OAB. Subjects were randomly assigned to receive 84mg/day oxybutynin, 56mg/day oxybutynin, or placebo. A total of 214 patients received 84mg/day oxybutynin, 210 patients received 56 mg/day oxybutynin, and 202 patients received placebo gel. The majority of patients were Caucasian (87%) and female (87%), with a mean age of 59 years (range: 19 to 89 years). The primary efficacy endpoint was the change from baseline to week 12 in the number of urinary incontinence episodes (UIE) per week, as determined from a 3-day patient daily diary.

Patients treated with ANTUROL (84 mg) experienced a statistically significant decrease in the number of urinary incontinence episodes per week from baseline to endpoint (the primary efficacy endpoint) compared with placebo (p=0.0445) and patients treated with the 56 mg dose did not show statistically significant efficacy. Statistically significant improvements in daily urinary frequency (p=0.0010) and urinary void volume (p < 0.0001) were also seen with ANTUROL (84 mg) relative to placebo. The mean difference from placebo for ANTUROL (84 mg) was -2.3 for urinary incontinence episodes per week in a group of patients with a mean of greater than 40 incontinence episodes per week at baseline. Mean and median change from baseline in weekly incontinence episodes (primary endpoint), daily urinary frequency, and urinary void volume (secondary endpoints) between placebo and ANTUROL are summarized in Table 3.

Table 3: Mean (SD) and median change from baseline to Week 12 in incontinence episodes, urinary frequency, and urinary void volume: Intent-To-Treat population (LOCF*)

Parameter	Placebo (N=202)		Anturol Gel (84 mg/day) (N=214)
	Mean (SD)	Median	Mean (SD)	Median
Weekly Urinary Incontinence Episodes
Baseline	45.8 (31.87)	40.9	43.6 (27.90)	37.3
Reduction	-18.1 (28.81)	-14.0	-20.4 (24.39)	-16.4
Mean difference [Anturol – placebo] (SE)			-2.3 (2.65)
P-value† vs. placebo			0.0445a
Daily Urinary Frequency
Baseline	11.5 (3.34)	11.0	11.3 (2.87)	10.7
Reduction	-1.9(3.34)	-1.7	-2.6 (2.66)	-2.3
Mean difference [Anturol – placebo] (SE)			-0.7 (0.30)
P-value† vs. placebo			0.0010b
Urinary Void Volume (mL)
Baseline	184.5 (85.71)	173.4	196.9 (88.11)	189.2
Increase	9.8 (64.98)	5.7	32.7 (77.25)	26.6
Mean difference [Anturol – placebo] (SE)			23.0 (7.24)
P-value† vs. placebo			< 0.0001b
*Last-Observation-Carried-Forward imputation for missing data †p-value is based on ANCOVA analysis on rank-transformed data a Comparison is significant if p ≤ 0.05 b Comparison is significant if p ≤ 0.0125, adjusting for multiplicity